Most people do not think continually about the likelihood of accident, injury, disease, and death, either to themselves or to those close to them. Under certain circumstances, however, some of these risks to life and health become more salient than they had previously been, and this in turn may alter the perception of their relative… Continue reading Reporting Hazards: their Benefits and Costs

The cost-effectiveness of each of the six hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors currently available was studied. For a cohort of patients between the ages of 60 and 85 years with coronary heart disease (CHD) who were taking atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, or simvastatin, the number of survivors, the annual direct cost per survivor, and… Continue reading Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction

Background The recommendation of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) to lower blood pressure (BP) in diabetic patients to less than 130/85 mm Hg may have negative economic consequences. A formal cost-effectiveness analysis was therefore performed, comparing the costs and potential… Continue reading Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients

Study objectives: The Clean Air Act Amendments of 1990 requires that chemical facilities in the US with specified quantities of certain toxic or flammable chemicals file a five year history of accidents. This study considers the relation between the reported accidents and surrounding community characteristics. Design: This study is a retrospective analysis of the association… Continue reading Environmental justice: frequency and severity of US chemical industry accidents and the socioeconomic status of surrounding communities